Nanna Acquisition Gives Astellas Mitochondrial Expertise
Pays Up To $86m For Platform And R&D
Japanese firm pays cash plus milestones for UK specialist as it looks to integrate novel screening platform and gain know-how in mitochondrial modulators with potential applications.
You may also be interested in...
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.